7-Hydroxymitragynine (7-OH) is a naturally occurring alkaloid associated with the kratom plant (Mitragyna speciosa). It is present naturally at very low levels, while some modern commercial products contain concentrated or enhanced amounts that differ considerably from traditional kratom leaf. The FDA specifically distinguishes naturally occurring trace 7-OH from products containing added or enhanced concentrations.

7-OH and Vape Formulations

In a 7-OH vape formulation, the compound is incorporated into a product designed to generate an aerosol for inhalation. This delivery format is different from traditional kratom powders, capsules, and oral extracts.

For researchers, the distinction is important because inhalation introduces additional questions about aerosol composition, thermal stability, respiratory exposure, absorption, and metabolism. A 2026 publication in Toxicological Sciences specifically identified 7-OH and kratom vaping products as an emerging public-health concern.

Why Formulation Matters

The chemical profile of a commercial 7-OH product cannot necessarily be determined from its label alone. Recent analytical research found substantial differences between labeled and measured 7-OH concentrations in some commercial products and detected additional oxidation products.

Researchers therefore have an interest in examining both the original formulation and the aerosol produced from it. Questions surrounding heating-related chemical changes and inhalation exposure remain areas requiring further investigation.

7-OH Compared With Natural Kratom

Natural kratom contains numerous alkaloids, with mitragynine generally being the predominant compound. 7-OH is a minor constituent of the plant, meaning concentrated 7-OH products can have a substantially different alkaloid profile from ordinary botanical kratom.

A 2026 study of nonswallowed kratom-derived products also found that vaping products represented the largest category in its sample, with most containing 7-OH. The researchers noted that clinical, safety, and pharmacokinetic data for these products remain limited.

Current Research and Regulation

The FDA states that 7-OH products have not been proven safe or effective for any medical use and recommends avoiding products containing concentrated 7-OH. U.S. regulatory attention has also increased, with a 2026 DEA temporary-scheduling process covering 7-OH above a proposed threshold and several related synthetic compounds.

Conclusion

7-Hydroxymitragynine is a potent kratom-related alkaloid that has become the subject of increasing scientific and regulatory attention. When incorporated into vape products, researchers must consider more than the compound itself, including formulation composition, aerosol chemistry, thermal stability, inhalation exposure, analytical testing, and the limited availability of long-term safety data.